Good Morning, Traders!…👋

U.S. stock futures climbed on Tuesday, boosted by optimism that a potential reprieve from auto tariffs could lift sentiment ahead of the next round of corporate earnings.
On Monday, U.S. stocks rose after a particularly volatile week for the markets.

This rally followed news that the Trump administration would treat tariffs on key electronics separately from duties on specific countries, with the tariffs to be imposed at a later date. The president also floated the idea of possible tariff exemptions for car companies, which helped send auto stocks soaring.

However, clarity around Trump’s trade policies remains elusive, as he also moved forward with plans to impose tariffs on pharmaceutical and semiconductor imports.
Traders are keeping a close eye on any early signs of how the ongoing tariff turmoil might affect corporate profits, as well as any guidance companies can offer for the upcoming quarters.

Earnings Watch

Earnings land today from Bank of America $BAC ( ▲ 0.28% ), Citigroup $C ( ▲ 0.4% ), and Johnson & Johnson $JNJ ( ▼ 0.23% )  before open, plus United Airlines $UAL ( ▼ 1.23% )  and Interactive Brokers $IBKR ( ▲ 0.14% )  after close.

Analysts expect Bank of America to hit $0.82 EPS on lending strength, Citigroup to deliver $1.85 EPS, J&J to post $2.59 EPS with pharma gains, United to soar with $0.75 EPS, and IBKR to shine at $1.76 EPS.

Happening Today

✓ 08:30 AM ET – Import & Export Price Index (MoM) (Mar)

✓ 08:30 AM ET – NY Empire State Manufacturing Index (Apr)

✓ 04:30 PM ET – API Weekly Crude Oil Stock

PREMARKET SNAPSHOT 📈

​U.S. stock futures are slightly lower ahead of the open, with the S&P 500, Dow, and Nasdaq all edging down as investors weigh ongoing trade policy developments and await key corporate earnings reports. ​

SECTOR SNAPSHOT✨

Markets extended their gains yesterday, with nearly all sectors finishing in the green. Real estate and utilities led the rally, while financials, healthcare, and industrials posted solid advances above 1%. Technology and materials also contributed to the upward momentum, whereas consumer discretionary was the only sector to dip slightly.

PreMarket Unusual Volume Stocks

📈 Healthcare Triangle, Inc. $HCTI is experiencing unusual early action with a 17% gain and 529.76K shares traded, compared to its 5.35K average. This sharp volume surge hints at strong speculative interest in the stock.

📈 ARB IOT Group Limited $ARBB has jumped over 33% in pre-market trading, supported by 8.11M shares exchanged—well above its 134.59K average. The stock’s breakout signals heightened attention from momentum traders.

📈 TMC the metals company Inc. $TMC is up more than 8% with 470.53K in volume against an average of 33.58K. The stock’s early strength and volume indicate bullish positioning, possibly ahead of a corporate update or macro catalyst.

📈 Verve Therapeutics, Inc. $VERV is gaining nearly 18% with 120.25K shares traded versus its 9.01K average. This spike suggests renewed optimism around the gene editing player heading into the session.

📈 Synergy CHC Corp. $SNYR is soaring 184% pre-market with 14.33M shares traded—dwarfing its 1.27M average. This explosive move places it firmly on the radar as a top speculative runner of the day.

Premarket Picks

ARB IOT Group Limited (ARBB) surged 35.01% in pre-market trading, reaching $0.86. The jump follows news that the company secured an approximately $53 million order for supplying AI servers, sparking investor enthusiasm.

Iterum Therapeutics plc (ITRM) rose 15.04% to $1.30 pre-market after presenting a scientific poster at ECCMID 2025. The presentation focused on how age impacts antibiotic resistance and the efficacy of treatments, drawing attention to its clinical research.

Newsmax, Inc. (NMAX) climbed 7.81% to $28.03, continuing its rally from yesterday. The momentum comes after the company announced a multi-year contract extension with Greta Van Susteren to continue hosting "The Record."

Verve Therapeutics, Inc. (VERV) jumped 14.32% to $4.71 after the company released encouraging initial data from its Heart-2 Phase 1b trial for VERVE-102, boosting investor confidence in its gene-editing therapies.

Below is a complete list of hot stocks in pre-market today:

Top Upgrades:

1. TotalEnergies SE $TTE ( ▲ 1.13% ) 

Analyst Firm: BNP Paribas Exane
Upgraded: Neutral to Outperform
Price Target: $62.44
Yesterday's Close: $56.75

BNP Paribas Exane raised its rating on TotalEnergies from Neutral to Outperform, setting a price target of $62.44. TotalEnergies SE, a global energy company involved in oil, gas, renewables, and electricity, has received a range of analyst stock price targets. The high estimate sits at $97.29, with a median of $71.65 and a low of $60.00. The average target is $73.49.

2. HubSpot, Inc. $HUBS ( ▲ 2.5% )  

Analyst Firm: UBS
Upgraded: Neutral to Buy
Price Target: $675
Yesterday's Close: $527.56

UBS analyst Taylor McGinnis boosted HubSpot's rating from Neutral to Buy, assigning a new price target of $675. HubSpot, Inc., known for its cloud-based CRM platform used by businesses worldwide, has a high stock price target of $980.00. Analysts estimate a median of $880.00, a low of $610.00, and an average price of $840.50.

3. Victory Capital Holdings, Inc. $VCTR ( ▼ 1.06% )  

Analyst Firm: B. Riley
Upgraded: Neutral to Buy
Price Target: $70.00
Yesterday's Close: $55.77

B. Riley upgraded Victory Capital from Neutral to Buy and increased the price target to $70, up from the previous $60. Victory Capital Holdings, an asset management firm with both U.S. and global operations, has an analyst high target of $87.00. The median estimate is $70.00, the low is $60.00, and the average target is $71.38.

Happy investing,

Maeve Grace
Editor In Chief
Premium Stock Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.